Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: A meta-analysis of randomized clinical trials

Introduction: The aim of this systematic review and meta-analysis was to summarize all the existing randomized controlled trials (RCTs) evidence and to evaluate the effects of green cardamom on lipoproteins, glycemic control and anthropometric parameters in healthy and/or with disease types compared with the control. Method: Two independent authors systematically searched online databases including EMBASE, Scopus, PubMed, Cochrane Library, and Web of Science from inception until 30th July 2019. RCTs complying with the following criteria were included in this meta-analysis: human trials with either cross-over design or parallel design, trials with data on the effects of green cardamom on serum lipoproteins and glycemic control and anthropometric parameters with standard deviation and related 95 confidence interval for the both intervention and placebo groups. The heterogeneity among the included studies was assessed using Cochrane's Q test and I-square (I2) statistic. Data were pooled using a random-effects model and weighted mean difference (WMD) was considered as the overall effect size. Result: Seven trials were included in this meta-analysis. Triglycerides were significantly reduced after cardamom supplementation when compared with the control group. Cardamom intake from 3 small studies resulted in a significant increase in BMI when compared with the control group. However, cardamom supplementation did not have any significant effect on total cholesterol, LDL-cholesterol, HDL-cholesterol, fasting plasma glucose and body weight when compared with the control group. Conclusion: This meta-analysis demonstrated that green cardamom intake significantly reduced triglycerides levels which may have played an indirect role in improved clinical symptoms in diseases with metabolic disorders. © 2020 European Society for Clinical Nutrition and Metabolis

Dietary intake and lifestyle behavior in different phenotypes of polycystic ovarian syndrome: a case-control study

Objective: To compare dietary intake and lifestyle behaviour in women with polycystic ovarian syndrome (PCOS) and healthy women. Methods: 160 healthy women (partner with male infertility) were recruited to a control group; 168 women with PCOS (diagnosed on ultrasound) were recruited to a case study group for this cross-sectional comparative study. The case group was classified into three phenotypes based on presence or absence of menstrual disorder (M), hyperandrogenism (HA), and polycystic ovary according to sonography (PCO): HA+PCO (n=53), PCO+M (n=57) and M+HA+PCO (n=66). Dietary intake and lifestyle behaviour were measured using a food frequency questionnaire (FFQ) and a lifestyle questionnaire (LQ). Results: The mean energy (P<0.001) and fat intake (P<0.001) were greater in PCOS groups compared with the control group. The average energy and fat intake were greater in HA+M+PCO group after age and BMI adjustment compared with other phenotypes (P<0.001). In comparison with the control group, lifestyle scores were lower in the PCOS group in the fields of physical activity, weight and nutrition control after age and BMI adjustment (P<0.001). The average score of lifestyle in the fields of physical activity, weight and nutrition control, and psychological health was lower in the phenotype HA+M+PCO compared with other phenotypes (P<0.001). Conclusions: Limited energy and fat intake is strongly recommended in Iranian women with PCOS especially in phenotype HA+M+PCO. Consultation on improvement of psychological health and the importance of weight and nutrition control, and appropriate physical activity in patients especially in HA+M+PCO is advocated. Keywords: Lifestyle, polycystic ovarian syndrome, die

Chitosan-Based Nanoparticles Against Viral Infections

Viral infections, in addition to damaging host cells, can compromise the host immune system, leading to frequent relapse or long-term persistence. Viruses have the capacity to destroy the host cell while liberating their own RNA or DNA in order to replicate within additional host cells. The viral life cycle makes it challenging to develop anti-viral drugs. Nanotechnology-based approaches have been suggested to deal effectively with viral diseases, and overcome some limitations of anti-viral drugs. Nanotechnology has enabled scientists to overcome the challenges of solubility and toxicity of anti-viral drugs, and can enhance their selectivity towards viruses and virally infected cells, while preserving healthy host cells. Chitosan is a naturally occurring polymer that has been used to construct nanoparticles (NPs), which are biocompatible, biodegradable, less toxic, easy to prepare, and can function as effective drug delivery systems (DDSs). Furthermore, chitosan is Generally Recognized as Safe (GRAS) by the US Food and Drug Administration (U.S. FDA). Chitosan NPs have been used in drug delivery by the oral, ocular, pulmonary, nasal, mucosal, buccal, or vaginal routes. They have also been studied for gene delivery, vaccine delivery, and advanced cancer therapy. Multiple lines of evidence suggest that chitosan NPs could be used as new therapeutic tools against viral infections. In this review we summarize reports concerning the therapeutic potential of chitosan NPs against various viral infections. © Copyright © 2021 Boroumand, Badie, Mazaheri, Seyedi, Nahand, Nejati, Baghi, Abbasi-Kolli, Badehnoosh, Ghandali, Hamblin and Mirzaei

Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial

Background: The present randomized clinical trial characterized the beneficial effects of a multi-strain probiotics supplementation on improving circulating endotoxin levels (primary endpoint) and other cardiometabolic biomarkers (secondary endpoint) in patients with T2DM. Methods: A total of 78 adult Saudi T2DM patients (naïve and without co-morbidities) participated in this clinical trial and were randomized to receive twice daily placebo or probiotics [(2.5 × 109 cfu/g) containing the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 (Ecologic®Barrier)] in a double-blind manner for 12 weeks. Anthropometrics and cardiometabolic profiles were obtained at baseline and after 12/13 weeks of treatment. Results: After 12/13 weeks of intervention and using intention-to-treat analysis, no difference was noted in endotoxin levels between groups [Placebo − 9.5% vs. Probiotics − 52.2%; (CI − 0.05 to 0.36; p = 0.15)]. Compared with the placebo group however, participants in the probiotics groups had a significant but modest improvement in WHR [Placebo 0.0% vs. Probiotics 1.11%; (CI − 0.12 to − 0.01; p = 0.02)] as well as a clinically significant improvement in HOMA-IR [Placebo − 12.2% vs. Probiotics − 60.4%; (CI − 0.34 to − 0.01; p = 0.04)]. Conclusion: Using a multi-strain probiotic supplement daily for 12/13 weeks significantly improved HOMA-IR and modestly reduced abdominal adiposity among medication naïve T2DM patients

Inhibitory effects of berberine on ovarian cancer: Beyond apoptosis

Ovarian cancer is one of the main causes of women�s mortality worldwide. A variety of biological mechanisms are involved in ovarian cancer pathogenesis, including epigenetic alterations, mutations (especially in tumor suppressor genes), upregulated oncogenes, decreased apoptotic pathways, and dysregulation of other signaling pathways. Surgery and chemotherapy are two common approaches for treating ovarian cancer. Chemoresistance to common therapeutic drugs results in a lack of significant improvements in ovarian cancer therapy. In this regard, finding and developing new therapeutic platforms are required. Utilizing medicinal plants has emerged as a new horizon in the treatment of various cancers, such as ovarian cancer. Berberine is a yellow extract obtained from different plants and shows various antitumor activities. Also, clinical studies indicated that berberine is a safe and nontoxic compound. Herein, we reviewed the role of berberine in different aspects of ovarian cancers, such as apoptosis. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature

Curcumin anti�tumor effects on endometrial cancer with focus on its molecular targets

Curcumin is extracted from turmeric and shows a variety of properties that make it a useful agent for treating diseases and targeting different biological mechanisms, including apoptosis, angiogenesis, inflammation, and oxidative stress. This phenolic compound is safe even at high doses. However, it has poor bioavailability. The incidence rates of endometrial cancer (EC) that is one of the most prevalent gynecological malignancies is increasing. Meanwhile, the onset age of EC has been decreased in past few years. Besides, EC does not show a convenient prognosis, particularly at advanced stages. Based on this information, discovering new approaches or enhancing the available ones is required to provide better care for EC patients. In this review, we cover studies concerned with the anti-tumor effects of curcumin on EC. We focus on molecular mechanisms that are targeted by curcumin treatment in different processes of cancer development and progression, such as apoptosis, inflammation, and migration. Furthermore, we present the role of curcumin in targeting some microRNAs (miRNAs) that may play a role in EC. © 2021, The Author(s)

The effects of Vitamin D supplementation on glycemic control, lipid profiles and c-reactive protein among patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials

Background: Insulin resistance, dyslipidemia and chronic inflammation are important risk factors for cardiovascular diseases (CVD). Hence, vitamin D supplementation might be an appropriate approach to decrease the complications of CVD. This systematic review and meta-analysis aimed to determine the effects of vitamin D supplementation on glycemic control, lipid profiles, and C-reactive protein among patients with coronary artery disease. Methods: Two independent authors systematically searched online databases including EMBASE, Scopus, Pub- Med, Cochrane Library, and Web of Science until 20th September 2018. Cochrane Collaboration risk of bias tool was applied to assess the methodological quality of included trials. The heterogeneity among the included studies was assessed using Cochran�s Q test and I-square (I2) statistic. Data were pooled using a random-effects model and weighted mean difference (WMD) was considered as the overall effect size. Results: A total of eight trials (305 participants in the intervention group and 325 in placebo group) were included in the current meta-analysis. Pooling effect sizes from studies revealed a significant reduction in fasting glucose (WMD): -15.67; 95 CI: -29.32, -2.03), insulin concentrations (WMD: -3.53; 95 CI: -4.59, -2.46) and homeostatic model assessment of insulin resistance (WMD: -1.07; 95 CI: -1.49, -0.66), and significant increase in the quantitative insulin-sensitivity check index (WMD: 0.02; 95 CI: 0.01, 0.03) following the administration of vitamin D. In addition, pooled analysis revealed a significant increase in serum HDL-cholesterol concentrations following vitamin D therapy (WMD: 3.08; 95 CI: 1.42, 4.73). Additionally, vitamin D supplementation significantly reduced C-reactive protein (CRP) levels (WMD: -0.75; 95 CI: -1.28, -0.23). Conclusion: This meta-analysis demonstrated the beneficial effects of vitamin D supplementation on improving glycemic control, HDL-cholesterol and CRP levels among patients with CVD, though it did not affect triglycerides, total- and LDL-cholesterol levels. © 2019 Bentham Science Publishers

Curcumin anti�tumor effects on endometrial cancer with focus on its molecular targets

Curcumin is extracted from turmeric and shows a variety of properties that make it a useful agent for treating diseases and targeting different biological mechanisms, including apoptosis, angiogenesis, inflammation, and oxidative stress. This phenolic compound is safe even at high doses. However, it has poor bioavailability. The incidence rates of endometrial cancer (EC) that is one of the most prevalent gynecological malignancies is increasing. Meanwhile, the onset age of EC has been decreased in past few years. Besides, EC does not show a convenient prognosis, particularly at advanced stages. Based on this information, discovering new approaches or enhancing the available ones is required to provide better care for EC patients. In this review, we cover studies concerned with the anti-tumor effects of curcumin on EC. We focus on molecular mechanisms that are targeted by curcumin treatment in different processes of cancer development and progression, such as apoptosis, inflammation, and migration. Furthermore, we present the role of curcumin in targeting some microRNAs (miRNAs) that may play a role in EC. © 2021, The Author(s)